Terms: = Ovarian cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Staging
3 results:
1. Metabolic-Related Gene Prognostic Index for Predicting Prognosis, Immunotherapy Response, and Candidate Drugs in ovarian cancer.
Guo S; Liu Y; Sun Y; Zhou H; Gao Y; Wang P; Zhi H; Zhang Y; Gan J; Ning S
J Chem Inf Model; 2024 Feb; 64(3):1066-1080. PubMed ID: 38238993
[TBL] [Abstract] [Full Text] [Related]
2. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
[TBL] [Abstract] [Full Text] [Related]
3. Correlation of pd-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer.
Tan D; Sheng L; Yi QH
Cancer Biomark; 2018 Feb; 21(2):287-297. PubMed ID: 29171986
[TBL] [Abstract] [Full Text] [Related]